
Early Trial Shows Type 1 Diabetics Can Stop Insulin Using New Anti-Rejection Drug
An early-stage clinical trial has demonstrated that individuals with Type 1 diabetes can discontinue insulin therapy after receiving an experimental medication designed to prevent organ transplant rejection. The treatment aims to restore natural insulin production by suppressing the immune system's attack on pancreatic beta cells, offering a potential functional cure rather than just management. While experts express cautious optimism regarding the initial results, they emphasize that further research is required to confirm long-term safety and efficacy before widespread adoption.












